1-20 of 38
ibrutinib
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Development and characterization of prototypes for in vitro and in vivo mouse models of ibrutinib-resistant CLL

Burcu Aslan, Gorkem Kismali, Lisa S. Chen, LaKesla R. Iles, Mikhila Mahendra, Michael Peoples, Mihai Gagea, Natalie W. Fowlkes, Xiaofeng Zheng, Jing Wang, Christopher P. Vellano, Joseph R. Marszalek, Maria Teresa Sabrina Bertilaccio, Varsha Gandhi
Journal: Blood Advances
Blood Adv (2021) 5 (16): 3134–3146.
https://doi.org/10.1182/bloodadvances.2020003821
Published: 2021
Includes: Supplemental data
Journal Articles

Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib

Paul J. Hampel, Hua-Jay J. Cherng, Timothy G. Call, Wei Ding, Mahsa Khanlari, Ellen D. McPhail, Roberto N. Miranda, Pei Lin, Hussein A. Tawbi, Alessandra Ferrajoli, William G. Wierda, Nitin Jain, Sameer A. Parikh
Journal: Blood Advances
Blood Adv (2020) 4 (18): 4508–4511.
https://doi.org/10.1182/bloodadvances.2020002454
Published: 2020
Includes: Supplemental data
Journal Articles

Targeting phosphatidylinositol 3 kinase-β and -δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma

Neeraj Jain, Satishkumar Singh, Georgios Laliotis, Amber Hart, Elizabeth Muhowski, Kristyna Kupcova, Tereza Chrbolkova, Tamer Khashab, Sayan Mullick Chowdhury, Anuvrat Sircar, Fazal Shirazi, Ram Kumar Singh, Lapo Alinari, Jiangjiang Zhu, Ondrej Havranek, Philip Tsichlis, Jennifer Woyach, Robert Baiocchi, Felipe Samaniego, Lalit Sehgal
Journal: Blood Advances
Blood Adv (2020) 4 (18): 4382–4392.
https://doi.org/10.1182/bloodadvances.2020001685
Published: 2020
Includes: Supplemental data
Journal Articles

Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS

Clinical Trials & Observations
Gerwin Huls, Dana A. Chitu, Thomas Pabst, Saskia K. Klein, Georg Stussi, Laimonas Griskevicius, Peter J. M. Valk, Jacqueline Cloos, Arjan A. van de Loosdrecht, Dimitri Breems, Danielle van Lammeren-Venema, Isabelle van Zeventer, Rinske Boersma, Mojca Jongen-Lavrencic, Martin Fehr, Mels Hoogendoorn, Markus G. Manz, Maaike Söhne, Rien van Marwijk Kooy, Dries Deeren, Marjolein W. M. van der Poel, Marie Cecile Legdeur, Lidwine Tick, Yves Chalandon, Emanuele Ammatuna, Sabine Blum, Bob Löwenberg, Gert J. Ossenkoppele
Journal: Blood Advances
Blood Adv (2020) 4 (18): 4267–4277.
https://doi.org/10.1182/bloodadvances.2020002846
Published: 2020
Includes: Supplemental data
Journal Articles

Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents

Lindsey E. Roeker, Peter Dreger, Jennifer R. Brown, Oscar B. Lahoud, Toby A. Eyre, Danielle M. Brander, Alan Skarbnik, Catherine C. Coombs, Haesook T. Kim, Matthew Davids, Steven T. Manchini, Gemlyn George, Nirav Shah, Timothy J. Voorhees, Kim H. Orchard, Harriet S. Walter, Arvind K. Arumainathan, Andrea Sitlinger, Jae H. Park, Mark B. Geyer, Andrew D. Zelenetz, Craig S. Sauter, Sergio A. Giralt, Miguel-Angel Perales, Anthony R. Mato
Journal: Blood Advances
Blood Adv (2020) 4 (16): 3977–3989.
https://doi.org/10.1182/bloodadvances.2020001956
Published: 2020
Journal Articles

Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors

Clinical Trials & Observations
Christine E. Ryan, Matthew P. Cheng, Nicolas C. Issa, Jennifer R. Brown, Matthew S. Davids
Journal: Blood Advances
Blood Adv (2020) 4 (7): 1458–1463.
https://doi.org/10.1182/bloodadvances.2020001678
Published: 2020
Journal Articles

The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites

Clinical Trials & Observations
Anthony Mato, Chadi Nabhan, Nicole Lamanna, Neil E. Kay, David L. Grinblatt, Christopher R. Flowers, Charles M. Farber, Matthew S. Davids, Arlene S. Swern, Kristen Sullivan, E. Dawn Flick, Sarah M. Gressett Ussery, Mecide Gharibo, Pavel Kiselev, Jeff P. Sharman
Journal: Blood Advances
Blood Adv (2020) 4 (7): 1407–1418.
https://doi.org/10.1182/bloodadvances.2019001145
Published: 2020
Includes: Supplemental data
Journal Articles

Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program

Clinical Trials & Observations
Georg Gelbenegger, Christian Schoergenhofer, Ulla Derhaschnig, Nina Buchtele, Christian Sillaber, Michael Fillitz, Thomas M. Schenk, Shirley D’Sa, Ronwyn Cartwright, James C. Gilbert, Bernd Jilma, Ulrich Jaeger
Journal: Blood Advances
Blood Adv (2020) 4 (6): 997–1005.
https://doi.org/10.1182/bloodadvances.2019001321
Published: 2020
Includes: Supplemental data
Journal Articles

Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin α IIb β 3 in mice and humans

Gasim Dobie, Fahd A. Kuriri, Musab M. A. Omar, Fehaid Alanazi, Ali M. Gazwani, Chloe P. S. Tang, Daniel Man-yuen Sze, Sasanka M. Handunnetti, Constantine Tam, Denise E. Jackson
Journal: Blood Advances
Blood Adv (2019) 3 (24): 4298–4311.
https://doi.org/10.1182/bloodadvances.2019000640
Published: 2019
Includes: Supplemental data
Journal Articles

Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcγRIIA): a new option in HIT?

Luise Goldmann, Rundan Duan, Thorsten Kragh, Georg Wittmann, Christian Weber, Reinhard Lorenz, Philipp von Hundelshausen, Michael Spannagl, Wolfgang Siess
Journal: Blood Advances
Blood Adv (2019) 3 (23): 4021–4033.
https://doi.org/10.1182/bloodadvances.2019000617
Published: 2019
Includes: Supplemental data
Journal Articles

Clonal dynamics in chronic lymphocytic leukemia

Catherine Gutierrez, Catherine J. Wu
Journal: Blood Advances
Blood Adv (2019) 3 (22): 3759–3769.
https://doi.org/10.1182/bloodadvances.2019000367
Published: 2019
Journal Articles

CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia

Joshua N. Gustine, Lian Xu, Nicholas Tsakmaklis, Maria G. Demos, Amanda Kofides, Jiaji G. Chen, Xia Liu, Manit Munshi, Maria Luisa Guerrera, Gloria G. Chan, Christopher J. Patterson, Andrew Keezer, Kirsten Meid, Toni Dubeau, Guang Yang, Zachary R. Hunter, Steven P. Treon, Jorge J. Castillo
Journal: Blood Advances
Blood Adv (2019) 3 (19): 2800–2803.
https://doi.org/10.1182/bloodadvances.2019000635
Published: 2019
Includes: Supplemental data
Journal Articles

Low-dose radiation (4 Gy) with/without concurrent chemotherapy is highly effective for relapsed, refractory mantle cell lymphoma

Clinical Trials & Observations
Matthew S. Ning, Chelsea C. Pinnix, Bhavana V. Chapman, Jillian R. Gunther, Sarah A. Milgrom, Joseph D. Khoury, Preetesh Jain, Wendy Y. Chen, Onyeka N. Oriabure, Maria R. Badillo, L. Michael Wang, Bouthaina S. Dabaja
Journal: Blood Advances
Blood Adv (2019) 3 (13): 2035–2039.
https://doi.org/10.1182/bloodadvances.2019030858
Published: 2019
Journal Articles

Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies

Clinical Trials & Observations
Steven E. Coutre, John C. Byrd, Peter Hillmen, Jacqueline C. Barrientos, Paul M. Barr, Stephen Devereux, Tadeusz Robak, Thomas J. Kipps, Anna Schuh, Carol Moreno, Richard R. Furman, Jan A. Burger, Michael O’Dwyer, Paolo Ghia, Rudolph Valentino, Stephen Chang, James P. Dean, Danelle F. James, Susan M. O’Brien
Journal: Blood Advances
Blood Adv (2019) 3 (12): 1799–1807.
https://doi.org/10.1182/bloodadvances.2018028761
Published: 2019
Includes: Supplemental data
Journal Articles

A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL

Clinical Trials & Observations
Anthony R. Mato, Lindsey E. Roeker, Toby A. Eyre, Chadi Nabhan, Nicole Lamanna, Brian T. Hill, Danielle M. Brander, Paul M. Barr, Frederick Lansigan, Bruce D. Cheson, Arun K. Singavi, Maryam Sarraf Yazdy, Nirav N. Shah, John N. Allan, Erica B. Bhavsar, Joanna Rhodes, Kaitlin Kennard, Stephen J. Schuster, AnnaLynn M. Williams, Alan P. Skarbnik, Andre H. Goy, Julie M. Goodfriend, Colleen Dorsey, Catherine C. Coombs, Hande Tuncer, Chaitra S. Ujjani, Ryan Jacobs, Allison M. Winter, John M. Pagel, Neil Bailey, Anna Schuh, Mazyar Shadman, Andrea Sitlinger, Hanna Weissbrot, Sivraj Muralikrishnan, Andrew Zelenetz, Amy A. Kirkwood, Christopher P. Fox
Journal: Blood Advances
Blood Adv (2019) 3 (10): 1568–1573.
https://doi.org/10.1182/bloodadvances.2019000180
Published: 2019
Journal Articles

Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib

Clinical Trials & Observations
Farrukh T. Awan, Anna Schuh, Jennifer R. Brown, Richard R. Furman, John M. Pagel, Peter Hillmen, Deborah M. Stephens, Jennifer Woyach, Elena Bibikova, Prista Charuworn, Melanie M. Frigault, Ahmed Hamdy, Raquel Izumi, Bolan Linghu, Priti Patel, Min Hui Wang, John C. Byrd
Journal: Blood Advances
Blood Adv (2019) 3 (9): 1553–1562.
https://doi.org/10.1182/bloodadvances.2018030007
Published: 2019
Journal Articles

Interleukin-2–inducible T-cell kinase inhibitors modify functional polarization of human peripheral T-cell lymphoma cells

Sami Mamand, Matthew Carr, Rebecca L. Allchin, Matthew J. Ahearne, Simon D. Wagner
Journal: Blood Advances
Blood Adv (2019) 3 (5): 705–710.
https://doi.org/10.1182/bloodadvances.2018027821
Published: 2019
Includes: Supplemental data
Journal Articles

Resistance mechanism for ibrutinib in marginal zone lymphoma

Clinical Trials & Observations
Narendranath Epperla, Arwa Y. Shana’ah, Dan Jones, Beth A. Christian, Sabarish Ayyappan, Kami Maddocks, Jennifer A. Woyach
Journal: Blood Advances
Blood Adv (2019) 3 (4): 500–502.
https://doi.org/10.1182/bloodadvances.2018029058
Published: 2019
Includes: Supplemental data
Journal Articles

Anti–BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib

Emily M. McWilliams, Christopher R. Lucas, Timothy Chen, Bonnie K. Harrington, Ronni Wasmuth, Amanda Campbell, Kerry A. Rogers, Carolyn M. Cheney, Xiaokui Mo, Leslie A. Andritsos, Farrukh T. Awan, Jennifer Woyach, William E. Carson, III, Jonathan Butchar, Susheela Tridandapani, Erin Hertlein, Carlos E. Castro, Natarajan Muthusamy, John C. Byrd
Journal: Blood Advances
Blood Adv (2019) 3 (3): 447–460.
https://doi.org/10.1182/bloodadvances.2018025684
Published: 2019
Includes: Supplemental data
Journal Articles

Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy

Clinical Trials & Observations
Daniel J. Landsburg, Mitchell E. Hughes, Alexa Koike, David Bond, Kami J. Maddocks, Ling Guo, Allison M. Winter, Brian T. Hill, Sarah L. Ondrejka, Eric D. Hsi, Sunita D. Nasta, Jakub Svoboda, Stephen J. Schuster, Agata M. Bogusz
Journal: Blood Advances
Blood Adv (2019) 3 (2): 132–135.
https://doi.org/10.1182/bloodadvances.2018026401
Published: 2019